NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Xeris Biopharma Holdings, Inc. XERS
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$291.8M
▲ 43.7% vs FY2024
EPS · FY25
$0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
0.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 291.8M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
0 cents of every revenue dollar became profit this year.
Per share
USD 0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin8.5%
Net margin0.2%
Return on assets0.2%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+70.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+38.3%
+70.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.17B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 383.5M
total assets, end of FY2025
Total assetsUSD 383.5M
EquityUSD 13.7M
CashUSD 111.0M
Gross debtUSD 220.3M
Net debtUSD 109.3M
Current ratio2.19×
Net debt stands at 798% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.3
0.2
0.2
0.1
0.0
0.0
Operating income $B
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
EBITDA $B
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
Income tax $B
0.0
−0.0
−0.0
−0.0
0.0
−0.0
Net income $B
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
0.00
−0.37
−0.45
−0.70
−1.55
−2.14
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
·
−324.2
−134.8
−190.3
−270.0
Shares out B
0.17
0.15
0.14
0.14
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
17 of 17
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed